Last $16.23 USD
Change Today +0.54 / 3.44%
Volume 683.1K
RGLS On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

regulus therapeutics inc (RGLS) Key Developments

Regulus and Sanofi Present New Data Enhancing the Preclinical Profile of RG-012, an Anti-miR Targeting microRNA-21 for the Treatment of Renal Dysfunction in Alport Syndrome Patients, at ASN's Kidney Week 2014 Meeting

Regulus Therapeutics Inc. announced that positive new preclinical data was presented on RG-012 for the treatment of renal dysfunction in Alport syndrome patients at the American Society of Nephrology's (ASN) Kidney Week 2014 meeting being held November 11-16, 2014 in Philadelphia, PA. Alport syndrome is a life-threatening, genetic kidney disease with no approved therapy, and currently, ACE (angiotensin-converting enzyme) inhibitors are emerging as standard of care to treat proteinuria, an indicator of chronic kidney disease (CKD) in these patients. Studies have shown that miR-21 plays a role in the progression of Alport syndrome and is up-regulated in mouse disease models, other renal fibrosis models and human CKD patients. These findings, and the new preclinical data presented at the ASN meeting, provide additional evidence that RG-012 may provide therapeutic benefit in the treatment of Alport syndrome. In an oral presentation titled "Anti-miR-21 as a Potential Novel Therapy for Both Early and Late Stages of Alport Syndrome", Regulus' strategic alliance partner, Genzyme, a Sanofi company, presented new data demonstrating that treatment with RG-012 in a mouse model of disease improves renal function, protects against kidney damage and extents the lifespan of the mice when treatment begins at both early and late stages of the disease by reversing multiple dysregulated pathways. Further, combination studies were performed with RG-012 and ramipril, Sanofi's ACE inhibitor, a kidney protectant, to assess the therapeutic utility of adding a microRNA therapeutic to this emerging standard of care. In these preclinical studies, treatment with RG-012 was shown to protect kidney function better than ramipril alone and an additive therapeutic effect was observed in combination with ramipril.

Regulus Therapeutics Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Full Year 2014

Regulus Therapeutics Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue of $1.083 million compared to $6.118 million a year ago. Loss from operations was $11.659 million compared to $2.905 million a year ago. Loss before income taxes was $9.798 million compared to $2.169 million a year ago. Net loss was $9.798 million or $0.26 per diluted share compared to $2.164 million or $0.07 per diluted share a year ago. Consistent with prior periods revenues primarily reflect the amortization of upfront payments received from strategic alliances and collaborations which was recognized over the estimated period of performance. For the nine months, the company reported total revenue of $3.450 million compared to $14.115 million a year ago. Loss from operations was $35.377 million compared to $13.140 million a year ago. Loss before income taxes was $34.511 million compared to $16.745 million a year ago. Net loss was $34.512 million or $0.80 per diluted share compared to $16.741 million or $0.45 per diluted share a year ago. The company also increased year-end guidance to end 2014 with now greater than $150 million in cash.

Regulus Therapeutics Inc. to Report Q3, 2014 Results on Nov 05, 2014

Regulus Therapeutics Inc. announced that they will report Q3, 2014 results at 5:00 PM, US Eastern Standard Time on Nov 05, 2014

Regulus Therapeutics Inc., Q3 2014 Earnings Call, Nov 05, 2014

Regulus Therapeutics Inc., Q3 2014 Earnings Call, Nov 05, 2014

Regulus Mulls Acquisitions

Regulus Therapeutics Inc. (NasdaqGM:RGLS) is seeking acquisitions. Regulus is offering $80 million of its common stock. Regulus may also use a portion of the net proceeds to in-license, acquire or invest in complementary microRNA businesses, technologies, products or assets.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGLS:US $16.23 USD +0.54

RGLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$0.74 AUD +0.005
Galena Biopharma Inc $2.07 USD +0.21
Prosensa Holding NV $11.44 USD -0.07
Silence Therapeutics PLC 200.00 GBp 0.00
Tekmira Pharmaceuticals Corp C$17.90 CAD -0.35
View Industry Companies
 

Industry Analysis

RGLS

Industry Average

Valuation RGLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 79.1x
Price/Book 9.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 76.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGULUS THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.